Author:
Dosquet Hugo,Neirinckx Virginie,Meyrath Max,Wantz May,Haan Serge,Niclou Simone P.,Szpakowska Martyna,Chevigné Andy
Reference37 articles.
1. Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism;Abourehab;Molecules,2021
2. The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective;Ahmadi;Nature Communications,2022
3. Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC;Bhalla;Journal of Clinical Oncology,2022
4. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with (1)(2)(5)I-EGF;Bjorkelund;PLoS One,2011
5. Comprehensive genomic characterization defines human glioblastoma genes and core pathways;Cancer Genome Atlas Research, N;Nature,2008